Breast cancer proteomics: a review for clinicians

Galvão, E. R. C. G. N.; Martins, Luana Mota; Ibiapina, Jerúsia Oliveira; Andrade, Hélida Monteiro de; Monte, Semíramis Jamil Hadad do

doi:10.1007/s00432-011-0978-0

Cited by 40 publications

(29 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, another immunological process uses antibodies that inactivate cancer-specific proteins, such as growth factors or tumor cell receptors that are important to tumor cells (research done on breast & ovarian cancer and drug discovered for receptor protein called HER2). [7] …”

Section: Existing Therapies and New Ideasmentioning

confidence: 99%

Bio-Informatics – Review on Current Research and Evolution of Cancer Targeted Therapies

Chatterjee¹,

Kumar²,

Pahari³

2016

CAE

View full text Add to dashboard Cite

The statistics shows that 7 million people die each year worldwide from cancer related cases & by 2020 this number will be more than around 16 million as methods of cancer treatment & cancer classification have become most challenging. So, cancer has become a noted disease responsible for major death rate. 200 different types of cancers are identified but some of them like lung, liver, stomach, colorectal, breast, oesophagal are leading death count. More than 60% of world's total new cases occur in Africa, Asia and Central and South America per annum. These regions account for 70% of the world's cancer deaths by oesophagal cancers as reported by World Health Organization.This article reviews and discusses recent improvement in the treatment of cancer and the challenges that exist, in reduced cost & time. Development and use of bioinformatics, nanotechnology is essential for the future cancer therapeutics. Most cancer treatments work for limited number of patients and this is likely to remain true for many molecularly-targeted drugs. As a consequence, a large proportion of patients are deprived of effective treatments and it is a huge financial burden on our health care system. It is essential to develop accurate tools for delivering the right treatment to the right patient based on biological characterization of each patient's tumor. The integration of wet experiments and the use of bioinformatics analysis have become an important part of biological and clinical research of this century. If we don't pay attention to it in future we will find a cancer patient in each family across the world. Cancer cure is really difficult but not complete hopeless. A lot of researches are being carried out in the field of bio-informatics to open up new possibilities for cancer treatments.

show abstract

Section: Existing Therapies and New Ideasmentioning

confidence: 99%

Bio-Informatics – Review on Current Research and Evolution of Cancer Targeted Therapies

Chatterjee¹,

Kumar²,

Pahari³

2016

CAE

View full text Add to dashboard Cite

show abstract

“…In China, the incidence rate and mortality rate of breast cancer rank first and fifth, respectively, among all types of cancer (3). As with other types of cancer, breast cancer involves multiple genes and factors, including hormonal and reproductive factors such as progesterone and estrogen receptors (4). Therefore, it is important to determine appropriate markers in order to determine the molecular mechanism for its onset and progression.…”

Section: Introductionmentioning

confidence: 99%

Expression of Krüppel-like factor 4 in breast cancer tissues and its effects on the proliferation of breast cancer MDA-MB-231 cells

Song

Xing

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. The aim of the present study was to detect the expression of Krüppel-like factor 4 (KLF4) in breast cancer tissues and to evaluate the effect on the proliferation of breast cancer MDA-MB-231 cells. The expression of KLF4 protein in 239 breast cancer tissues and 40 paracancerous tissues were detected by an immunohistochemical assay, and its correlation with clinical pathological parameters was analyzed. A eukaryotic expression vector, pcDNA3.1-KLF4, was constructed by transient transfection of breast cancer MDA-MB-231 cells with liposomes (experimental group). The untransfected cells and those transfected with empty plasmid pcDNA3.1 were used as the blank and negative control groups, respectively. The expression of the KLF4 gene and protein in the three groups were detected by reverse transcription polymerase chain reaction and western blotting, respectively. Furthermore, the cell proliferative capacity was detected by an MTT assay. The positive expression rate of KLF4 protein in breast cancer tissues (39.0%, 93/239) was significantly lower than that of paracancerous tissues (77.5%, 31/40) (P<0.05). In addition, KLF4 protein expression in breast cancer tissues was correlated with pathological type, histological grade and lymphatic metastasis (P<0.05). KLF4 mRNA and protein were both expressed by the experimental group, but not by the two control groups. Meanwhile, the proliferative capacity of the experimental group was also significantly decreased. A significant decrease in the positive expression rate of KLF4 protein in breast cancer tissues was correlated with several clinical pathological parameters. In addition, transfection of the KLF4 gene inhibited the proliferation of breast cancer cells, suggesting that this gene is important in the onset and progression of this type of cancer.

show abstract

“…Despite the current limitations, proteomics-based biomarker discovery and validation are capable of improving the molecular knowledge of breast cancer and the creation of tissue-based or circulating diagnostic and prognostic clinical utilities (7). In this review, the current techniques applied to breast cancer studies and the most significant research results are summarized.…”

Section: Introductionmentioning

confidence: 99%

Proteomic studies in breast cancer (Review)

Qin

Ling

2012

Oncol Lett

View full text Add to dashboard Cite

Abstract. Breast cancer is one of the most common types of invasive cancer in females worldwide. Despite major advances in early cancer detection and emerging therapeutic strategies, further improvement has to be achieved for precise diagnosis to reduce the chance of metastasis and relapses. Recent proteomic technologies have offered a promising opportunity for the identification of new breast cancer biomarkers. Matrix-assisted laser desorption/ionization, time-of-flight mass spectrometry (MALDI-TOF MS) and the derived surface-enhanced laser desorption/ionization mass spectrometry (SELDI-TOF MS) enable the development of high-throughput proteome analysis based on comprehensive reliable biomarkers. In this review, we examined proteomic technologies and their applications, and provided focus on the proteomics-based profiling analyses of tumor tissues/cells in order to identify and confirm novel biomarkers of breast cancer.

show abstract

Breast cancer proteomics: a review for clinicians

Cited by 40 publications

References 81 publications

Bio-Informatics – Review on Current Research and Evolution of Cancer Targeted Therapies

Bio-Informatics – Review on Current Research and Evolution of Cancer Targeted Therapies

Expression of Krüppel-like factor 4 in breast cancer tissues and its effects on the proliferation of breast cancer MDA-MB-231 cells

Proteomic studies in breast cancer (Review)

Contact Info

Product

Resources

About